ChitogenX Inc. (CHNXF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -1.55 Million CAD | 75.06% |
| 2023 | -6.23 Million CAD | -26.6% |
| 2022 | -4.92 Million CAD | -30.46% |
| 2021 | -3.77 Million CAD | -51.61% |
| 2020 | -2.48 Million CAD | -3.73% |
| 2019 | -2.39 Million CAD | -18.65% |
| 2018 | -2.02 Million CAD | -21.71% |
| 2017 | -1.66 Million CAD | -79.02% |
| 2016 | -927.88 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -784 Thousand CAD | -91.69% |
| 2024 Q1 | 97 Thousand CAD | 104.49% |
| 2024 Q4 | -458 Thousand CAD | 41.58% |
| 2024 FY | -1.55 Million CAD | 75.06% |
| 2024 Q2 | -409 Thousand CAD | -521.65% |
| 2023 Q4 | -2.16 Million CAD | -16.32% |
| 2023 Q1 | -850 Thousand CAD | 0.23% |
| 2023 Q2 | -1.36 Million CAD | -60.35% |
| 2023 FY | -6.23 Million CAD | -26.6% |
| 2023 Q3 | -1.85 Million CAD | -36.24% |
| 2022 Q3 | -1.92 Million CAD | -112.72% |
| 2022 FY | -4.92 Million CAD | -30.46% |
| 2022 Q4 | -852 Thousand CAD | 55.69% |
| 2022 Q2 | -904 Thousand CAD | 27.16% |
| 2022 Q1 | -1.24 Million CAD | 2.13% |
| 2021 Q3 | -813 Thousand CAD | -28.84% |
| 2021 Q2 | -631 Thousand CAD | 40.47% |
| 2021 Q1 | -1.06 Million CAD | -122.69% |
| 2021 Q4 | -1.26 Million CAD | -55.97% |
| 2021 FY | -3.77 Million CAD | -51.61% |
| 2020 Q2 | -662 Thousand CAD | -12.2% |
| 2020 Q3 | -760 Thousand CAD | -14.8% |
| 2020 Q4 | -476 Thousand CAD | 37.37% |
| 2020 FY | -2.48 Million CAD | -3.73% |
| 2020 Q1 | -590 Thousand CAD | 13.85% |
| 2019 Q3 | -778 Thousand CAD | -60.74% |
| 2019 Q1 | -452 Thousand CAD | 55.06% |
| 2019 Q2 | -484 Thousand CAD | -7.08% |
| 2019 Q4 | -684.82 Thousand CAD | 11.98% |
| 2019 FY | -2.39 Million CAD | -18.65% |
| 2018 Q3 | -397.15 Thousand CAD | -9.73% |
| 2018 Q2 | -361.94 Thousand CAD | -40.95% |
| 2018 Q1 | -256.79 Thousand CAD | -26.23% |
| 2018 Q4 | -1 Million CAD | -153.24% |
| 2018 FY | -2.02 Million CAD | -21.71% |
| 2017 Q2 | -550.55 Thousand CAD | -101.89% |
| 2017 Q4 | -203.43 Thousand CAD | 57.04% |
| 2017 FY | -1.66 Million CAD | -79.02% |
| 2017 Q1 | -272.7 Thousand CAD | 59.17% |
| 2017 Q3 | -473.55 Thousand CAD | 13.99% |
| 2016 FY | -927.88 Thousand CAD | 0.0% |
| 2016 Q1 | -36.54 Thousand CAD | 0.0% |
| 2016 Q2 | -54.44 Thousand CAD | -48.99% |
| 2016 Q3 | -169.05 Thousand CAD | -210.5% |
| 2016 Q4 | -667.84 Thousand CAD | -295.05% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Accustem Sciences Inc. | -3.74 Million USD | 58.52% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 59.309% |
| Genus plc | 7.9 Million USD | 119.671% |
| LadRx Corporation | 400.44 Thousand USD | 488.07% |
| Enzolytics Inc. | -2.17 Million USD | 28.612% |
| Regen BioPharma, Inc. | 1.02 Million USD | 251.831% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 80.337% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 68.195% |
| Halberd Corporation | -79.67 Thousand USD | -1850.399% |
| Skye Bioscience, Inc. | -37.64 Million USD | 95.872% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.927% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 14.64% |
| Kadimastem Ltd | -3.3 Million USD | 53.014% |
| IMV Inc. | -36.48 Million USD | 95.741% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 10.041% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 102.386% |
| Zenith Capital Corp. | -10.59 Million USD | 85.334% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 97.398% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 60.886% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 76.369% |
| EV Biologics, Inc. | -1.26 Million USD | -22.639% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 58.371% |
| Q BioMed Inc. | -2.05 Million USD | 24.272% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 77.745% |
| Biomind Labs Inc. | -1.21 Million USD | -27.973% |
| SQZ Biotechnologies Company | -79.46 Million USD | 98.044% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -16.367% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -10276.603% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 58.116% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 34.73% |
| CSL Limited | 2.64 Billion USD | 100.059% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 82.429% |
| CytoDyn Inc. | -49.84 Million USD | 96.882% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -6586.172% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 122.442% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1685.714% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 20.277% |
| HST Global, Inc. | -146.21 Thousand USD | -962.855% |
| Helix BioMedix, Inc. | -1.05 Million USD | -47.151% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -468.394% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1866.267% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 96.994% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -581.2% |
| Affymax, Inc. | -14.42 Million USD | 89.226% |
| Alpha Cognition Inc. | -13.77 Million USD | 88.717% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Qrons Inc. | -789.34 Thousand USD | -96.872% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 80.719% |
| AVAX Technologies, Inc. | -6.41 Million USD | 75.77% |
| ContraFect Corporation | -65.15 Million USD | 97.615% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 62.518% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| SYBLEU INC | -180.3 Thousand USD | -761.878% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 102.933% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 28.381% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 85.732% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -2471.119% |
| NovAccess Global Inc. | -4.76 Million USD | 67.416% |
| Marizyme, Inc. | -65.34 Million USD | 97.622% |
| Mesoblast Limited | -87.95 Million USD | 98.233% |
| MultiCell Technologies, Inc. | -380.07 USD | -408772.05% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 46.273% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 90.209% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -145.728% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 85.267% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 73.286% |
| GB Sciences, Inc. | -1.36 Million USD | -14.124% |
| argenx SE | -295.05 Million USD | 99.473% |
| Resverlogix Corp. | -3.61 Million USD | 56.953% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 51.0% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.518% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 49.9% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 48.647% |
| ONE Bio Corp. | 8.67 Million USD | 117.91% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.372% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 22.498% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 11.441% |
| Agentix Corp. | -1.37 Million USD | -13.083% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 81.681% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -252.086% |
| Cell Source, Inc. | -5.32 Million USD | 70.796% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -274.026% |
| Regen BioPharma, Inc. | 1.02 Million USD | 251.831% |
| Itoco Inc. | -1.86 Million USD | 16.854% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 65.02% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 6.89% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -65.051% |
| Nascent Biotech, Inc. | -2.08 Million USD | 25.563% |
| Rebus Holdings, Inc. | -1.02 Million USD | -52.353% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 3.642% |
| Mobile Lads Corp. | -2.26 Million USD | 31.339% |
| International Stem Cell Corporation | -131 Thousand USD | -1086.26% |
| Bioxytran, Inc. | -4.28 Million USD | 63.692% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -2763.355% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 38.583% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 96.767% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 26.49% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -99.004% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 50.947% |
| Neutra Corp. | -233.46 Thousand USD | -565.624% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 92.341% |
| PureTech Health plc | -65.69 Million USD | 97.635% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 92.693% |
| IXICO plc | -1.17 Million USD | -31.919% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 84.346% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 97.28% |
| CSL Limited | 2.64 Billion USD | 100.059% |
| Cellectis S.A. | -103.17 Million USD | 98.494% |